孟加拉國第一大藥廠Beximco于2015年10月4日通過官方網站正式發布消息，旗下出品的Lesovir-C吉二代仿制藥獲得注冊商標和美國FDA認證，正式亮相。BEXIMCO制藥僅以100字的簡短表述低調的發布了這條新聞。原文如下
Beximco Pharma has recently launched the revolutionary hepatitis C drug under the brand name Lesovir C which is a combination of Sofosbuvir and Ledipasvir.
This has been the first generic version in the world and the main objective is to make this latest and highly expensive medicine affordable to our patients. Lesovir C is available at tablet whereas the innovator brand Harvoni from Gilead Inc. costs around $1125 per tablet. The fixed dose combination ledipasvir-sofosbuvir (90 mg/400 mg) is FDA-approved for the treatment of chronic hepatitis C with a cure rate of about 95%.
譯文：Beximco制藥公司最近推出了品牌名稱下的革命丙型肝炎藥物Lesovir C Sofosbuvir和Ledipasvir的組合。這是世界上第一個通用版本,主要目標是使這一最新和高度昂貴的醫藥能夠讓貧窮的病人負擔的起。Lesovir C一個療程的費用不到品牌專利藥旗下的藥物兩片的費用，每片1125美元。固定劑量組合ledipasvir-sofosbuvir(90毫克/ 400毫克)是美國FDA批準的用于治療慢性丙型肝炎的治愈率高達95%的產品。
Beximco Pharma has recently launched the revolutionary hepatitis C drug under the brand name Lesovir C which is a combination of Sofosbuvir and Ledipasvir.
This has been the first generic version in the world and the main objective is to make this latest and highly expensive medicine affordable to our patients. Lesovir C is available at tablet whereas the innovator brand Harvoni from Gilead Inc. costs around $1125 per tablet. The fixed dose combination ledipasvir-sofosbuvir (90 mg/400 mg) is FDA-approved for the treatment of chronic hepatitis C with a cure rate of about 95%.
譯文：Beximco制藥公司最近推出了品牌名稱下的革命丙型肝炎藥物Lesovir C Sofosbuvir和Ledipasvir的組合。這是世界上第一個通用版本,主要目標是使這一最新和高度昂貴的醫藥能夠讓貧窮的病人負擔的起。Lesovir C一個療程的費用不到品牌專利藥旗下的藥物兩片的費用，每片1125美元。固定劑量組合ledipasvir-sofosbuvir(90毫克/ 400毫克)是美國FDA批準的用于治療慢性丙型肝炎的治愈率高達95%的產品。
